Taken together, our data clearly indicated that rTMS may benefit for the treatment of dyskinesia in PD through rescuing the degenerative dopaminergic neurons and avoiding the fluctuations of striatal dopamine level via promoting the GDNF expression. The gene discussed is GDNF; the disease is drug-induced dyskinesia.